Akihiro Inazu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2326192/publications.pdf

Version: 2024-02-01

		87843	82499
137	5,720	38	72
papers	citations	h-index	g-index

146	146	146	4536
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Increased High-Density Lipoprotein Levels Caused by a Common Cholesteryl-Ester Transfer Protein Gene Mutation. New England Journal of Medicine, 1990, 323, 1234-1238.	13.9	802
2	Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature, 1989, 342, 448-451.	13.7	476
3	Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol.. Journal of Clinical Investigation, 1994, 94, 1872-1882.	3.9	226
4	A Low Prevalence of Coronary Heart Disease among Subjects with Increased High-Density Lipoprotein Cholesterol Levels, Including Those with Plasma Cholesteryl Ester Transfer Protein Deficiency. Preventive Medicine, 1998, 27, 659-667.	1.6	163
5	Circulating Matrix Metalloproteinases and Their Inhibitors in Premature Coronary Atherosclerosis. Clinical Chemistry and Laboratory Medicine, 2001, 39, 380-4.	1.4	137
6	Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. European Heart Journal, 2017, 38, 1573-1579.	1.0	132
7	Postprandial lipoprotein metabolism: VLDL vs chylomicrons. Clinica Chimica Acta, 2011, 412, 1306-1318.	0.5	124
8	Marked Aortic Valve Stenosis Progression After Receiving Long-Term Aggressive Cholesterol-Lowering Therapy Using Low-Density Lipoprotein Apheresis in a Patient With Familial Hypercholesterolemia. Circulation Journal, 2009, 73, 963-966.	0.7	112
9	Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clinical Science, 2002, 103, 587-594.	1.8	111
10	Reduction of Serum Ubiquinol-10 and Ubiquinone-10 Levels by Atorvastatin in Hypercholesterolemic Patients. Journal of Atherosclerosis and Thrombosis, 2005, 12, 111-119.	0.9	107
11	Association of Estrogen Receptor-Î± Gene Polymorphisms With Coronary Artery Disease in Patients With Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 817-823.	1.1	99
12	Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan. Atherosclerosis, 2011, 214, 404-407.	0.4	99
13	Serum lipoprotein lipid concentration and composition in homozygous and heterozygous patients with cholesteryl ester transfer protein deficiency. Atherosclerosis, 1991, 90, 189-196.	0.4	92
14	Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: A randomized double-blind study. Atherosclerosis, 2007, 195, e182-e189.	0.4	92
15	Sitosterolemia, Hypercholesterolemia, and Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 2018, 25, 783-789.	0.9	90
16	Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. Journal of Lipid Research, 2004, 45, 448-455.	2.0	89
17	Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease. Journal of Clinical Lipidology, 2018, 12, 1436-1444.	0.6	81
18	Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation. Atherosclerosis, 2014, 236, 54-61.	0.4	78

#	Article	IF	Citations
19	Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis, 2002, 163, 157-164.	0.4	71
20	Impacts of Visceral Adipose Tissue and Subcutaneous Adipose Tissue on Metabolic Risk Factors in Middleâ€aged Japanese. Obesity, 2010, 18, 153-160.	1.5	70
21	Abetalipoproteinemia Caused by Maternal Isodisomy of Chromosome 4q Containing an Intron 9 Splice Acceptor Mutation in the Microsomal Triglyceride Transfer Protein Gene. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1950-1955.	1.1	68
22	Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. Circulation Research, 2017, 121, 81-88.	2.0	68
23	Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (<i>PCSK9</i>) Gain-of-Function Mutations. Circulation Journal, 2016, 80, 512-518.	0.7	67
24	Comparison of waist circumference with body mass index for predicting abdominal adipose tissue. Diabetes Research and Clinical Practice, 2009, 83, 100-105.	1.1	65
25	Molecular genetic analysis of familial hypercholesterolemia: spectrum and regional difference of LDL receptor gene mutations in Japanese population. Atherosclerosis, 2002, 165, 335-342.	0.4	64
26	The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis, 2010, 210, 166-172.	0.4	62
27	Assessment of Coronary Atherosclerosis in Patients With Familial Hypercholesterolemia by Coronary Computed Tomography Angiography. American Journal of Cardiology, 2015, 115, 724-729.	0.7	60
28	Alternative splicing of the mRNA encoding the human cholesteryl ester transfer protein. Biochemistry, 1992, 31, 2352-2358.	1.2	59
29	Haplotype analyses of cholesteryl ester transfer protein gene promoter: a clue to an unsolved mystery of TaqIB polymorphism. Journal of Molecular Medicine, 2003, 81, 246-255.	1.7	52
30	Cholesteryl ester transfer protein and atherosclerosis. Current Opinion in Lipidology, 2000, 11, 389-396.	1.2	49
31	Cholesteryl Ester Transfer Protein Activity Enhances Plasma Cholesteryl Ester Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1045-1052.	1.1	49
32	Effects of serum B vitamins on elevated plasma homocysteine levels associated with the mutation of methylenetetrahydrofolate reductase gene in Japanese. Atherosclerosis, 2002, 164, 321-328.	0.4	48
33	Enhanced Cholesteryl Ester Transfer Protein Activities and Abnormalities of High Density Lipoproteins in Familial Hypercholesterolemia. Hormone and Metabolic Research, 1992, 24, 284-288.	0.7	47
34	Cholesteryl Ester Transfer Protein (CETP) Deficiency and CETP Inhibitors. Molecules and Cells, 2014, 37, 777-784.	1.0	46
35	Infantile Cases of Sitosterolaemia with Novel Mutations in the ABCG5 Gene: Extreme Hypercholesterolaemia is Exacerbated by Breastfeeding. JIMD Reports, 2015, 21, 115-122.	0.7	45
36	ATP-binding cassette transporter G8 M429V polymorphism as a novel genetic marker of higher cholesterol absorption in hypercholesterolaemic Japanese subjects. Clinical Science, 2005, 109, 183-188.	1.8	44

#	Article	IF	Citations
37	A novel type of familial hypercholesterolemia: Double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene. Atherosclerosis, 2011, 219, 663-666.	0.4	43
38	Altered Metabolism of Low-Density Lipoprotein and Very-Low-Density Lipoprotein Remnant in Autosomal Recessive Hypercholesterolemia. Circulation: Cardiovascular Genetics, 2012, 5, 35-41.	5.1	40
39	Relationship of Lipoprotein Lipase and Hepatic Triacylglycerol Lipase Activity to Serum Adiponectin Levels in Japanese Hyperlipidemic Men. Hormone and Metabolic Research, 2005, 37, 505-509.	0.7	39
40	Reduction of lipoprotein(a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia. Atherosclerosis, 1993, 100, 65-74.	0.4	38
41	Long-Term Course of Lipoprotein Lipase (LPL) Deficiency Due to Homozygous LPLAritain a Patient with Recurrent Pancreatitis, Retained Glucose Tolerance, and Atherosclerosis. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6541-6544.	1.8	38
42	Decreased post-prandial triglyceride response and diminished remnant lipoprotein formation in cholesteryl ester transfer protein (CETP) deficiency. Atherosclerosis, 2008, 196, 953-957.	0.4	38
43	Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study. Atherosclerosis, 2011, 217, 165-170.	0.4	38
44	Serum lipoprotein lipase mass: Clinical significance of its measurement. Clinica Chimica Acta, 2007, 378, 7-12.	0.5	36
45	Efficacy and Safety of Coadministration of Rosuvastatin, Ezetimibe, and Colestimide in Heterozygous Familial Hypercholesterolemia. American Journal of Cardiology, 2012, 109, 364-369.	0.7	35
46	Enzyme immunoassay for cholesteryl ester transfer protein in human serum. Clinica Chimica Acta, 1998, 271, 109-118.	0.5	34
47	Carotid artery intima-media thickness and brachial artery flow-mediated vasodilation in asymptomatic Japanese male subjects amongst apolipoprotein E phenotypes. Journal of Internal Medicine, 2002, 252, 114-120.	2.7	33
48	Hypolipidemic Effect of Pleurotus eryngii Extract in Fat-Loaded Mice. Journal of Nutritional Science and Vitaminology, 2010, 56, 48-53.	0.2	33
49	Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer protein deficiency. Atherosclerosis, 1997, 132, 229-236.	0.4	32
50	Comparison of Effects of Pitavastatin and Atorvastatin on Plasma Coenzyme Q10 in Heterozygous Familial Hypercholesterolemia: Results From a Crossover Study. Clinical Pharmacology and Therapeutics, 2008, 83, 731-739.	2.3	32
51	Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia. American Journal of Cardiology, 1998, 82, 113-A8.	0.7	31
52	Effect of Walking with a Pedometer on Serum Lipid and Adiponectin Levels in Japanese Middle-aged Men. Journal of Atherosclerosis and Thrombosis, 2006, 13, 197-201.	0.9	31
53	Effect of common methylenetetrahydrofolate reductase gene mutation on coronary artery disease in familial hypercholesterolemia. American Journal of Cardiology, 2000, 86, 840-845.	0.7	29
54	A novel method for measuring human lipoprotein lipase and hepatic lipase activities in postheparin plasma. Journal of Lipid Research, 2008, 49, 1431-1437.	2.0	29

#	Article	IF	Citations
55	Clinical characteristics of Japanese patients with severe hypertriglyceridemia. Journal of Clinical Lipidology, 2015, 9, 519-524.	0.6	29
56	Effects of hepatic lipase gene promoter nucleotide variations on serum HDL cholesterol concentration in the general Japanese population. Journal of Human Genetics, 2001, 46, 172-177.	1.1	28
57	Cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells to serum is preserved in CETP-deficient patients. Clinica Chimica Acta, 2009, 402, 19-24.	0.5	26
58	Formation of preÎ²1-HDL during lipolysis of triglyceride-rich lipoprotein. Biochemical and Biophysical Research Communications, 2009, 379, 55-59.	1.0	26
59	Assessments of Carotid Artery Plaque Burden in Patients With Familial Hypercholesterolemia. American Journal of Cardiology, 2017, 120, 1955-1960.	0.7	26
60	Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma. Atherosclerosis, 1999, 145, 405-413.	0.4	25
61	Rapid detection and prevalence of cholesteryl ester transfer protein deficiency caused by an intron 14 splicing defect in hyperalphalipoproteinemia. Human Genetics, 1993, 91, 13-6.	1.8	24
62	Lipid Management in a Japanese Community:Attainment Rate of Target Set by the Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases 2012. Journal of Atherosclerosis and Thrombosis, 2017, 24, 338-345.	0.9	24
63	Absence of familial defective apolipoprotein B-100 in Japanese patients with familial hypercholesterolaemia. Lancet, The, 1995, 345, 1438.	6.3	23
64	Identification of Two Novel Missense Mutations (p.R1221C and p.R1357W) in the ABCC6 (MRP6) Gene in a Japanese Patient with Pseudoxanthoma Elasticum (PXE). Internal Medicine, 2004, 43, 1171-1176.	0.3	23
65	The Relationship of Percent Body Fat by Bioelectrical Impedance Analysis with Blood Pressure, and Glucose and Lipid Parameters. Journal of Atherosclerosis and Thrombosis, 2006, 13, 221-226.	0.9	23
66	High Frequency of a Retinoid X Receptor Î³ Gene Variant in Familial Combined Hyperlipidemia That Associates With Atherogenic Dyslipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 923-928.	1.1	23
67	Remnant lipoproteins and atherosclerotic cardiovascular disease. Clinica Chimica Acta, 2019, 490, 1-5.	0.5	23
68	Autosomal Recessive Hypercholesterolemia: A Mild Phenotype of Familial Hypercholesterolemia: Insight from the Kinetic Study using Stable Isotope and Animal Studies. Journal of Atherosclerosis and Thrombosis, 2015, 22, 1-9.	0.9	22
69	Difference in the Risk Factors for Coronary, Renal and Other Peripheral Arteriosclerosis in Heterozygous Familial Hypercholesterolemia. Circulation Journal, 2004, 68, 623-627.	0.7	21
70	A novel method for determining functional LDL receptor activity in familial hypercholesterolemia: Application of the CD3/CD28 assay in lymphocytes. Clinica Chimica Acta, 2009, 400, 42-47.	0.5	21
71	Double deletions and missense mutations in the first nucleotide-binding fold of the ATP-binding cassette transporter A1 (ABCA1) gene in Japanese patients with Tangier disease. Journal of Human Genetics, 2002, 47, 325-329.	1.1	20
72	A Rare Coincidence of Sitosterolemia and Familial Mediterranean Fever Identified by Whole Exome Sequencing. Journal of Atherosclerosis and Thrombosis, 2016, 23, 884-890.	0.9	20

#	Article	IF	Citations
73	Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis. Atherosclerosis, 2017, 265, 225-230.	0.4	20
74	Cutoff Point Separating Affected and Unaffected Familial Hypercholesterolemic Patients Validated by LDL-receptor Gene Mutants. Journal of Atherosclerosis and Thrombosis, 2005, 12, 35-40.	0.9	20
75	Assessment of arterial stiffness in patients with familial hypercholesterolemia. Journal of Clinical Lipidology, 2018, 12, 397-402.e2.	0.6	18
76	Plasma homocysteine level and development of coronary artery disease. Coronary Artery Disease, 1999, 10, 443-448.	0.3	17
77	Dual effects on HDL metabolism by cholesteryl ester transfer protein inhibition in HepG2 cells. American Journal of Physiology - Endocrinology and Metabolism, 2003, 284, E1210-E1219.	1.8	17
78	CETP (cholesteryl ester transfer protein) promoter â^'1337 C>T polymorphism protects against coronary atherosclerosis in Japanese patients with heterozygous familial hypercholesterolaemia. Clinical Science, 2006, 111, 325-331.	1.8	17
79	Identification of a Novel Missense Mutation in the Sterol 27-Hydroxylase Gene in Two Japanese Patients with Cerebrotendinous Xanthomatosis. Internal Medicine, 2010, 49, 1127-1131.	0.3	16
80	Postâ€prandial remnant lipoprotein metabolism in autosomal recessive hypercholesterolaemia. European Journal of Clinical Investigation, 2012, 42, 1094-1099.	1.7	16
81	Whole exome sequencing combined with integrated variant annotation prediction identifies asymptomatic Tangier disease with compound heterozygous mutations in ABCA1 gene. Atherosclerosis, 2015, 240, 324-329.	0.4	16
82	Molecular and functional characterization of familial chylomicronemia syndrome. Atherosclerosis, 2018, 269, 272-278.	0.4	16
83	Difference between Fasting and Nonfasting Triglyceridemia; the Influence of Waist Circumference. Journal of Atherosclerosis and Thrombosis, 2009, 16, 633-640.	0.9	16
84	Removal of apolipoprotein E-enriched high density lipoprotein by LDL-apheresis in familial hypercholesterolaemia: a possible activation of the reverse cholesterol transport system. Atherosclerosis, 1988, 74, 1-8.	0.4	15
85	Detailed analysis of serum lipids and lipoproteins from Japanese type III hyperlipoproteinemia with apolipoprotein E2/2 phenotype. Clinica Chimica Acta, 2004, 348, 35-40.	0.5	15
86	Apolipoprotein B gene mutations and fatty liver in Japanese hypobetalipoproteinemia. Clinica Chimica Acta, 2009, 399, 64-68.	0.5	15
87	Remnant-like particles and coronary artery disease in familial hypercholesterolemia. Clinica Chimica Acta, 2018, 482, 120-123.	0.5	15
88	Efficacy of Colestimide Coadministered With Atorvastatin in Japanese Patients With Heterozygous Familial Hypercholesterolemia (FH). Circulation Journal, 2005, 69, 515-520.	0.7	14
89	Contribution of visceral adiposity and insulin resistance to metabolic risk factors in Japanese men. Metabolism: Clinical and Experimental, 2010, 59, 748-754.	1.5	14
90	Novel mutations of cholesteryl ester transfer protein (CETP) gene in Japanese hyperalphalipoproteinemic subjects. Clinica Chimica Acta, 2012, 413, 537-543.	0.5	14

#	Article	IF	Citations
91	Cholesterol-Years Score is Associated with Development of Senile Degenerative Aortic Stenosis in Heterozygous Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2006, 13, 323-328.	0.9	12
92	A deficiency of cholesteryl ester transfer protein whose serum remnant-like particle-triglyceride significantly increased, but serum remnant-like particle-cholesterol did not after an oral fat load. Annals of Clinical Biochemistry, 2009, 46, 457-463.	0.8	12
93	Extreme Contrast of Postprandial Remnant-Like Particles Formed in Abetalipoproteinemia and Homozygous Familial Hypobetalipoproteinemia. JIMD Reports, 2015, 22, 85-94.	0.7	12
94	Clinical efficacy of fluvastatin in thelong-term treatment of familial hypercholesterolemia. American Journal of Cardiology, 1995, 76, 47A-50A.	0.7	11
95	The Relationship of Serum Lipoprotein Lipase Mass with Fasting Serum Apolipoprotein B-48 and Remnant-like Particle Triglycerides in Type 2 Diabetic Patients. Hormone and Metabolic Research, 2007, 39, 612-616.	0.7	11
96	Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: Result from a crossover study. Clinica Chimica Acta, 2011, 412, 1068-1075.	0.5	11
97	Novel gene mutations at the low density lipoprotein receptor locus: FHâ€Kanazawa and FHâ€Okayama. Journal of Internal Medicine, 1990, 227, 247-251.	2.7	10
98	A novel method for measuring human hepatic lipase activity in postheparin plasma. Journal of Lipid Research, 2007, 48, 453-457.	2.0	10
99	Clinical significance of measuring soluble LR11, a circulating marker of atherosclerosis and HbA1c in familial hypercholesterolemia. Clinical Biochemistry, 2014, 47, 1326-1328.	0.8	10
100	Prevalence, clinical features, and prognosis of patients with extremely low high-density lipoprotein cholesterol. Journal of Clinical Lipidology, 2016, 10, 1311-1317.	0.6	9
101	A de novo mutation of the LDL receptor gene as the cause of familial hypercholesterolemia identified using whole exome sequencing. Clinica Chimica Acta, 2016, 453, 194-196.	0.5	9
102	Post-prandial Remnant Lipoprotein Metabolism in Sitosterolemia. Journal of Atherosclerosis and Thrombosis, 2018, 25, 1188-1195.	0.9	8
103	Serum sitosterol level predicting ABCG5 or ABCG8 genetic mutations. Clinica Chimica Acta, 2020, 507, 11-16.	0.5	8
104	Type III Hyperlipoproteinemia Exaggerated by Sheehan's Syndrome With Advanced Systemic Atherosclerosis A 28-Year Clinical Course. Circulation Journal, 2005, 69, 746-751.	0.7	7
105	Effects of Fenofibrate Therapy on Plasma Ubiquinol-10 and Ubiquinone-10 Levels in Japanese Patients with Hyperlipidemia and Type 2 Diabetes Mellitus. Pharmacotherapy, 2006, 26, 447-451.	1.2	7
106	Changes in lipoprotein lipase and endothelial lipase mass in familial hypercholesterolemia during three-drug lipid-lowering combination therapy. Lipids in Health and Disease, 2016, 15, 66.	1.2	7
107	Postprandial triglyceridaemia in men with impaired fasting glucose, impaired glucose tolerance and diabetes. Diabetic Medicine, 2008, 25, 1008-1010.	1.2	6
108	Compound heterozygote of cholesteryl-ester transfer protein deficiency in a patient with hyperalphalipoproteinemia. Atherosclerosis, 1992, 96, 83-85.	0.4	5

#	Article	IF	Citations
109	Lipoprotein metabolism in familial hypercholesterolemia: Serial assessment using a one-step ultracentrifugation method. Practical Laboratory Medicine, 2015, 1, 22-27.	0.6	5
110	Therapeutic implications of cholesteryl ester transfer protein inhibitors in hyperlipidemia and low high-density lipoprotein-cholesterolemia. Current Opinion in Investigational Drugs, 2003, 4, 291-7.	2.3	5
111	Marked Transient Hypercholesterolemia Caused by Low-dose Mitotane as Adjuvant Chemotherapy for Adrenocortical Carcinoma. Journal of Atherosclerosis and Thrombosis, 2014, 21, 1326-1329.	0.9	4
112	Clinical whole exome sequencing in severe hypertriglyceridemia. Clinica Chimica Acta, 2019, 488, 31-39.	0.5	4
113	Additive effects of another kind of HMG-CoA reductase inhibitor with different pharmacokinetics in the treatment of heterozygous familial hypercholesterolemia. Atherosclerosis, 2000, 153, 525-526.	0.4	3
114	Molecular Genetics of Cholesterol Transport and Cholesterol Reverse Transport Disorders (Familial) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Academy of Sciences, 1994, 748, 333-341.	1.8	3
115	Cholesteryl ester transfer protein inhibitors: new strategies for raising high-density lipoprotein cholesterol. Future Lipidology, 2006, 1, 487-500.	0.5	3
116	Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect. Current Drug Therapy, 2007, 2, 39-51.	0.2	3
117	Hokuriku-plus familial hypercholesterolaemia registry study: rationale and study design. BMJ Open, 2020, 10, e038623.	0.8	3
118	CETP(Cholesteryl Ester Transfer Protein) Deficiency Caused by Genetic Mutation in the CETP Gene in Normal Korean Population. Sunhwan'gi, 1996, 26, 500.	0.3	3
119	A teenager boy with a novel variant of Sitosterolemia presented with pancytopenia. Clinica Chimica Acta, 2022, 529, 61-66.	0.5	3
120	An unsolved mystery of promoter variation in CETP gene and atherosclerosis. European Journal of Clinical Investigation, 2001, 31, 558-559.	1.7	2
121	Plasma Cholesteryl Ester Transfer Protein (CETP) in Relation to Human Pathophysiology. , 2010, , 35-59.		2
122	HDL₃ Cholesterol Levels in an Elderly Population. Journal of Atherosclerosis and Thrombosis, 2018, 25, 40-41.	0.9	2
123	Prevalence, self-awareness, and LDL cholesterol levels among patients highly suspected as familial hypercholesterolemia in a Japanese community. Practical Laboratory Medicine, 2020, 22, e00181.	0.6	2
124	Corrigendum to â€œMolecular genetic analysis of familial hypercholesterolemia: spectrum and regional difference of LDL receptor gene mutations in Japanese populationâ€•[ATH 165 (2002) 335â€“342]. Atherosclerosis, 2004, 174, 399-400.	0.4	1
125	Cholesteryl Ester Transfer Protein Inhibitors. , 2014, , 195-220.		1
126	CETP Deficiency and Concerns in CETP Inhibitor Development. , 2017, , 23-35.		1

#	Article	IF	Citations
127	Abstract 1921: Clinical Impact of Heterozygous Carrier of Autosomal Recessive Hypercholesterolemia on Asymptomatic Hyperlipidemic Patients: Evidence From Familial Gene Analysis. Circulation, 2008, 118, .	1.6	1
128	Relationships between Alanine Aminotransferase(ALT), Visceral Adipose Tissue(AT) and Metabolic Risk Factors in a Middle-Aged Japanese Population. Journal of Atherosclerosis and Thrombosis, 2014, 21, .	0.9	1
129	The Effects of LDL-Apheresis and Plasma Exchange on Cholesterol Level and Lipid Composition of Low and High Density Lipoproteins in Homozygous Patients with Familial Hyper-Cholesterolemia. The Journal of Japan Atherosclerosis Society, 1988, 16, 53-57.	0.0	1
130	A 4-year trial of simvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. Current Therapeutic Research, 1996, 57, 62-71.	0.5	0
131	Common functional variant LIPA T16P affects HDL composition among patients with heterozygous familial hypercholesterolemia. Atherosclerosis, 2017, 263, e37-e38.	0.4	0
132	Common Mutation of 5, 10-Methylenetetrahydrofolate Reductase Accelerates Coronary Artery Disease in Familial Hypercholesterolemia. , 2000, , 62-64.		0
133	Human Cholesteryl Ester Transfer Protein in Human HDL Metabolism. , 2010, , 95-101.		0
134	Apolipoprotein A-I Gene Polymorphism in Patients with Coronary Heart Disease and Normolipidemic Controls. The Journal of Japan Atherosclerosis Society, 1987, 15, 1521-1525.	0.0	0
135	Effects of LDL-Apheresis on Coronary Artery Stenosis in Patients with Familial Hypercholesterolemia. The Journal of Japan Atherosclerosis Society, 1989, 17, 717-724.	0.0	0
136	Molecular Genetics of Cholesterol Transport and Cholesterol Reverse Transport Disorders, and Coronary Heart Disease. Medical Science Symposia Series, 1996, , 371-377.	0.0	0
137	Effects of Combined Therapy Using Two Kinds of HMG-CoA Reductase Inhibitors in Heterozygous Familial Hypercholesterolemia. The Journal of Japan Atherosclerosis Society, 1999, 27, 1-6.	0.0	0